As noted, some have found no low-grade DCIS was HER2 positive [39] and the more accurate identification of true low-risk DCIS may indeed require combinations of biomarkers rather than applying cytonuclear grade alone. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.